News Detail
Maryland, 7 Jan 2025: Following Viatris’ December announcement that a manufacturing plant in India had been written up by the FDA, a document published by the U.S. regulator reveals the details behind the company's manufacturing infractions.
In a warn......
View Details
Source : Fierce Pharma
Mylan
Viatris
India
U.S. FDA
FDA warning letter
FDA inspection
quality control
drug manufacturing
import alert
Facilities
Fierce Pharma Homepage
Manufacturing
Pharma
Related News
- Sun Pharma unit Taro to acquire 100% stake in Antibe Therapeutics (16-01-2025)
- Calcutta HC directs Paschim Banga Pharmaceuticals to stop manufacturing; state to compensate families (16-01-2025)
- FDA Revokes Use of 'FD&C Red No.3' in Foods and Drugs (16-01-2025)
- Dabur sues Patanjali over toothpaste trade dress (16-01-2025)
- Wrappers of drug brands found from Paonta printing press premises (16-01-2025)
- PCI revises list of pharmacists blocked on DIGI-PHARMed platform, asks to re-register (16-01-2025)
- Clear labelling of industrial & medical oxygen must, PMO tells health ministry (16-01-2025)
- Himachal to form Special Task Force to Combat Drug Abuse (16-01-2025)
- SC warns States/UTs of Contempt Proceedings over inaction on Misleading Advertisements (16-01-2025)
- 3600 Proxyvon capsule consignment going to Nepal caught (15-01-2025)